Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
about
Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compoundsPerifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagySolenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesisCell Proliferation in NeuroblastomaPhysiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug deliveryStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaMaximising the potential of AKT inhibitors as anti-cancer treatmentsMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsIn vitro models of cancer stem cells and clinical applicationsNovel therapeutic strategies for multiple myelomaThe critical role of Akt in cardiovascular functionTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayEvaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.Dysregulation of cell polarity proteins synergize with oncogenes or the microenvironment to induce invasive behavior in epithelial cellsMolecular imaging of phosphorylation events for drug developmentA novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.Akt inhibitors: mechanism of action and implications for anticancer therapeutics.The PIK3CA gene as a mutated target for cancer therapy.A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsNovel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.Small-molecule inhibitors of the PI3K signaling networkInvestigational agents in development for the treatment of ovarian cancerCD81 is essential for the re-entry of hematopoietic stem cells to quiescence following stress-induced proliferation via deactivation of the Akt pathwaySelective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Akt: a double-edged sword in cell proliferation and genome stability.Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesotheliomaBiological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylationRevealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arraysThe Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.Novel targeted therapies for the treatment of metastatic melanoma.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Targeting the PI3K/Akt/mTOR pathway--beyond rapalogsPerifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cellsMolecular imaging with activatable reporter systemsSilencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation.Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options
P2860
Q21136097-5C4E8D44-FBA4-44F8-933A-E2FCB77F82FCQ24645466-ED1C5F47-38C1-4721-87BD-953224D38795Q24681382-357D7706-8B2C-4CA5-844B-CE959D6FAD94Q26771708-DFA95B55-45FD-452F-A262-70241FEFE18BQ26861408-7F698A24-9375-4F6C-8D76-2A09E0B7CC18Q27026544-AEC19C77-7016-4F0D-8367-00AFC39B517FQ28072254-E8D038F2-D54F-4DC2-A040-FB8596D018CFQ28075606-05F713B0-1FF2-4627-BB87-A82E1A1C3C49Q28076101-9A50A463-92F7-4D9B-A566-E2E190E9E532Q28081590-64878DC5-F564-4EB4-B70B-F919B8135A62Q28083829-3D32EF17-C86F-4B74-B3A8-8B40219E1692Q28382812-65BC52E3-3E37-4A3D-B054-1C81F40833F4Q30663984-066E8676-DB59-4AAC-872A-1393D8CE4686Q31056323-1BB71A7B-9D48-4E32-8224-A4B08697FBF9Q33388737-B84DFC47-AE9D-4EFB-9BF5-A9508243516AQ33620076-A1A23B63-A635-451C-94F7-6904C498CE63Q33641026-A3C8E599-AD91-43C3-A9A9-8DB2DC32734BQ33699378-A2C3E8F8-DC8D-42CC-83F7-F006FC4907D3Q33707181-AB88429F-4C6D-480D-B49B-87FFD7F19116Q33764664-4D6AF191-9BC9-4DEC-841C-3782E831E83DQ33882138-2AD358C8-89C5-48DE-ACED-BF9927C82E66Q33883982-F5922EAF-777B-4EC4-A554-008131CB1D0FQ33920800-F456B604-D848-4926-85A9-573699DD9869Q34022970-F3CF313B-1543-459D-9033-DD92587AAD9DQ34075096-E59401E3-0B3D-4BEC-8338-81382C580C15Q34223641-ED897B31-81DA-4551-B495-CB8FDE1E43EBQ34271064-4AE6E168-BB63-48AB-9F01-65762948633BQ34278085-B7BC99E3-A54C-4113-8CBA-B66E3A92734EQ34307356-EC0775E0-D380-4ABE-94B4-0B444ABB18AFQ34361586-959B319A-7655-4F7C-82A8-081BB024A87FQ34412619-800D4500-1B81-458D-980B-578D0F4CC41FQ34758583-2CDCD210-11A1-47CB-805A-05AEEC58E970Q34986178-4D68EEFA-B130-43EE-A5F1-599D4471081BQ35583942-017BA11D-EF67-44A0-A998-47FFCD84DA78Q35640098-04101714-90C3-4F74-8459-1297B47C2357Q35741309-8B56E4F5-B11C-4CBB-AAD8-A5C575284080Q35744471-B80C8C48-49BC-4E7E-8F52-9EAD24F19E17Q35915786-D3148397-29E3-4928-9BDD-4A122763ECDCQ36135521-B1E3A3AD-D76D-4763-97CB-87F081357B18Q36237715-61E762BF-8ACC-4094-9D44-D5D0DC43F040
P2860
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
description
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
scientific journal article
@en
vedecký článok (publikovaný 2003/11/01)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/11/01)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована в листопаді 2003
@uk
مقالة علمية (نشرت في نوفمبر 2003)
@ar
name
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@ast
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@en
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@nl
type
label
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@ast
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@en
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@nl
prefLabel
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@ast
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@en
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@nl
P2093
P3181
P1476
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
@en
P2093
Edward A. Sausville
Girija P. Dasmahapatra
Krishnendu K. Roy
Sheo S. Singh
Sudhir B. Kondapaka
P304
P3181
P577
2003-11-01T00:00:00Z